TY - JOUR

T1 - Plasma oxylipin profiles reflect Parkinson's disease stage

AU - Chistyakov, D.V.

AU - Azbukina, N.V.

AU - Lopachev, A.V.

AU - Goriainov, S.V.

AU - Astakhova, A.A.

AU - Ptitsyna, E.V.

AU - Klimenko, A.S.

AU - Poleshuk, V.V.

AU - Kazanskaya, R.B.

AU - Fedorova, T.N.

AU - Sergeeva, M.G.

N1 - Export Date: 21 March 2024 CODEN: POLMF Адрес для корреспонденции: Chistyakov, D.V.; Belozersky Institute of Physico-Chemical Biology, Russian Federation; эл. почта: chistyakof@gmail.com Химические вещества/CAS: 12 hydroxyicosatetraenoic acid, 54397-83-0, 59985-28-3, 71030-37-0; anandamide, 94421-68-8; arachidonic acid, 506-32-1, 6610-25-9, 7771-44-0; hydroxyicosatetraenoic acid, 69845-60-9; leukotriene E4, 75715-89-8; Arachidonic Acid; Fatty Acids, Unsaturated; Oxylipins Сведения о финансировании: Russian Foundation for Basic Research, РФФИ, 19–29–01243 Текст о финансировании 1: The reported study was funded by the RFBR according to the research project No. 19–29–01243 .

PY - 2024/4/1

Y1 - 2024/4/1

N2 - Derivatives of polyunsaturated fatty acids (PUFAs), also known as oxylipins, are key participants in regulating inflammation. Neuroinflammation is involved in many neurodegenerative diseases, including Parkinson's disease. The development of ultra-high-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) facilitated the study of oxylipins on a system level, i.e., the analysis of oxylipin profiles. We analyzed oxylipin profiles in the blood plasma of 36 healthy volunteers (HC) and 73 patients with Parkinson's disease (PD), divided into early (L\M, 29 patients) or advanced (H, 44 patients) stages based on the Hoehn and Yahr scale. Among the 40 oxylipins detected, we observed a decrease in the concentration of arachidonic acid (AA) and AA derivatives, including anandamide (AEA) and Leukotriene E4 (LTE4), and an increase in the concentration of hydroxyeicosatetraenoic acids 19-HETE and 12-HETE (PD vs HC). Correlation analysis of gender, age of PD onset, and disease stages revealed 20 compounds the concentration of which changed depending on disease stage. Comparison of the acquired oxylipin profiles to openly available PD patient brain transcriptome datasets showed that plasma oxylipins do not appear to directly reflect changes in brain metabolism at different disease stages. However, both the L\M and H stages are characterized by their own oxylipin profiles – in patients with the H stage oxylipin synthesis is increased, while in patients with L\M stages oxylipin synthesis decreases compared to HC. This suggests that different therapeutic approaches may be more effective for patients at early versus late stages of PD. © 2023 Elsevier Inc.

AB - Derivatives of polyunsaturated fatty acids (PUFAs), also known as oxylipins, are key participants in regulating inflammation. Neuroinflammation is involved in many neurodegenerative diseases, including Parkinson's disease. The development of ultra-high-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) facilitated the study of oxylipins on a system level, i.e., the analysis of oxylipin profiles. We analyzed oxylipin profiles in the blood plasma of 36 healthy volunteers (HC) and 73 patients with Parkinson's disease (PD), divided into early (L\M, 29 patients) or advanced (H, 44 patients) stages based on the Hoehn and Yahr scale. Among the 40 oxylipins detected, we observed a decrease in the concentration of arachidonic acid (AA) and AA derivatives, including anandamide (AEA) and Leukotriene E4 (LTE4), and an increase in the concentration of hydroxyeicosatetraenoic acids 19-HETE and 12-HETE (PD vs HC). Correlation analysis of gender, age of PD onset, and disease stages revealed 20 compounds the concentration of which changed depending on disease stage. Comparison of the acquired oxylipin profiles to openly available PD patient brain transcriptome datasets showed that plasma oxylipins do not appear to directly reflect changes in brain metabolism at different disease stages. However, both the L\M and H stages are characterized by their own oxylipin profiles – in patients with the H stage oxylipin synthesis is increased, while in patients with L\M stages oxylipin synthesis decreases compared to HC. This suggests that different therapeutic approaches may be more effective for patients at early versus late stages of PD. © 2023 Elsevier Inc.

KW - Anandamide

KW - Blood profiling

KW - COX

KW - Lipidomics

KW - Oxylipins

KW - Parkinson disease

KW - PUFAs

KW - Transcriptomics

KW - UPLC-MS/MS

KW - 12 hydroxyicosatetraenoic acid

KW - anandamide

KW - arachidonic acid

KW - arachidonic acid derivative

KW - hydroxyicosatetraenoic acid

KW - leukotriene E4

KW - oxylipin

KW - transcriptome

KW - unsaturated fatty acid

KW - adult

KW - Article

KW - brain metabolism

KW - brain tissue

KW - Brodmann area 9

KW - clinical feature

KW - cohort analysis

KW - comparative study

KW - controlled study

KW - degenerative disease

KW - differential gene expression

KW - fatty acid blood level

KW - female

KW - gender

KW - gene expression

KW - Hoehn and Yahr scale

KW - human

KW - human tissue

KW - lipidomics

KW - major clinical study

KW - male

KW - middle aged

KW - onset age

KW - liquid chromatography

KW - metabolism

KW - procedures

KW - tandem mass spectrometry

KW - Arachidonic Acid

KW - Chromatography, Liquid

KW - Fatty Acids, Unsaturated

KW - Humans

KW - Parkinson Disease

KW - Tandem Mass Spectrometry

UR - https://www.mendeley.com/catalogue/da8ad429-9f11-37fe-ba50-c97475b1d16c/

U2 - 10.1016/j.prostaglandins.2023.106788

DO - 10.1016/j.prostaglandins.2023.106788

M3 - статья

VL - 171

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

ER -